AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01767220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strategy 2 - endocardial and epicardial ablation
Description: VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
Study NCT02912364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine
Description: Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
Study NCT02912364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
Study NCT02544776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomifene citrate ( clomid 50 mg )
Study NCT02544776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomifene citrate ( clomid 50 mg )
Study NCT02544776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Study NCT03137979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMSCs and collagen scaffolds
Description: Patients in this group were given GMSCs and collagen scaffolds.
Study NCT03137979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagen scaffolds
Description: Patients in this group were given collagen scaffolds.
Study NCT03137979 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open flap debridement
Description: The patients in this group will only receive the treatment of open flap debridement.
Study NCT02036515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ertugliflozin 10 mg
Description: Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
Study NCT02641951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stellate ganglionic block
Description: Ultrasound guided stellate ganglionic block
Study NCT02641951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pecs II block
Description: Ultrasound guided Pecs II block
Study NCT05217823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Study NCT05217823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand instruments
Study NCT04095104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine tablet
Study NCT04095104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release Topiramate
Description: Topiramate tablet
Study NCT04095104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Phentermine
Description: Compounded tablet to mimic phentermine 8mg tablet
Study NCT04095104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Immediate Release Topiramate
Description: Compounded tablet to mimic immediate release topiramate 25mg tablet
Study NCT00238420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00238420 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00238420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT03172741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Marijuana
Description: 1-gram marijuana cigarette smoked once per day for 3 months
Study NCT03172741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 1 gram placebo cigarette smoked once per day for 3 months
Study NCT00859131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Antithymocyte globulin
Description: 1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
Study NCT00859131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: 1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
Study NCT00391014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal Amphotericine B
Description: AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed.
Study NCT00687661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate
Description: 35mg given orally once weekly for 24 months
Study NCT00687661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo pill once weekly for 24 months
Study NCT01119339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 dosage 1, once daily
Study NCT02154750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long, fixed AV delay
Description: Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
Study NCT02154750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short, optimized AV delay
Description: Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
Study NCT04567563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic conditioning (RIC)
Description: Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
Study NCT00342355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: 600 mg once daily
Study NCT00342355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 40 mg once daily
Study NCT00342355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Didanosine
Description: \<60 kg/125 mg twice daily or >60kg/200 mg twice daily
Study NCT03871361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept 125 MG/ML Prefilled Syringe
Description: Abatacept 125 MG/ML Prefilled Syringe \[Orencia\] weekly
Study NCT02704286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Osteoarthritis Risk Calculator
Description: The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.
Study NCT02704286 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Generic osteoarthritis information
Description: Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
Study NCT02093494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Initial Specimen Diversion Device (ISDD)
Study NCT02093494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lab standard practice (LSP)
Study NCT02093494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Intravenous Catheters (PIVC)
Study NCT01038661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV
Study NCT01038661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV
Study NCT01038661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care (BSC)
Description: Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator
Study NCT03282162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: Each subject will be assigned to intranasal administration of oxytocin (24 IU).
Study NCT03282162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: An identical amount of intranasal administration of placebo will be assigned to each subject.
Study NCT02682784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Nasal spray based on naturally occurring hormone, oxytocin.
Study NCT02682784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03476265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation of the Lower Esophageal Sphincter
Description: Laparoscopic implantation of an electrical stimulation device to perform an electrical sphincter augmentation for the treatment of GERD.
Study NCT02664103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT02017119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison between Lactulose and Lactulose-Paraffin
Study NCT03197285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EYE-CERVICAL RE-EDUCATION PROGRAM
Description: Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~1. To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~2. To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~3. Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses.
Study NCT01119339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 dosage 2, once daily
Study NCT01119339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 dosage 3, once daily
Study NCT01119339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 dosage 4, once daily
Study NCT01119339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004
Description: LAS 41004 , dosage 5, once daily
Study NCT01119339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41004 dosage 6
Description: LAS 41004, dosage 6, once daily
Study NCT01119339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily
Study NCT01119339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Reference, once daily
Study NCT03428815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthesis suspension liner
Description: Liners out of phase change material will be fitted
Study NCT03428815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis suspension liner
Description: Liners out of phase change material will be fitted
Study NCT04499417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyostimulation Whole-Body-Workout
Description: Electromyostimulation - intensity 5 (muscle stimulation)
Study NCT04499417 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electromyostimulation Sham Whole-Body-Workout
Description: Electromyostimulation - intensity 0 (no muscle stimulation)
Study NCT04223037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis Vaccine produced by IMBCAMS
Description: Dosage form: 0.5mL/vial
Study NCT04223037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Vaccine produced by IMBCAMS
Description: Dosage form: 0.5mL/vial
Study NCT03219463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger
Description: 3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
Study NCT04223037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Vaccine produced by Liaoning Chenda
Description: Dosage form: 0.5mL/vial
Study NCT02393755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT00342355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 300 mg once daily
Study NCT00342355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600 mg once daily
Study NCT00342355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: r/LPV 400mg/100mg twice daily
Study NCT02071238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pamphlet
Description: Written pamphlet outlining the risks of surgery as discussed in consultation.
Study NCT02071238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Consultation
Description: Informed consent discussion in group-format
Study NCT03392766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single lumen tube and bronchial blocker
Description: neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
Study NCT03392766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double lumen tube
Description: neck collar apply. fibreoptic intubation with double lumen tube.
Study NCT01832961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter valve exercises
Description: 30 minutes of flutter exercises
Study NCT01832961 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Flutter Sham exercises
Description: 30 minutes of flutter-sham exercises
Study NCT01832961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter and bronchodilator exercises
Description: Flutter + bronchodilator exercises with an interval of 3 to 5 days
Study NCT01832961 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Flutter and bronchodilator exercises
Description: Flutter + bronchodilator exercises with an interval of 3 to 5 days
Study NCT01058603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: - Conventional culture medium for IVF
Description: Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
Study NCT01058603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: - Endocell®
Description: Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
Study NCT02300649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, Transesophageal echocardiography(TEE)
Description: Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
Study NCT02300649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.
Study NCT01530139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 1
Description: Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
Study NCT02393755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02393755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study NCT02393755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03757923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB METFORMIN
Description: INSULIN SENSITIZING AGENTS
Study NCT01530139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 2
Description: Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
Study NCT01530139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 3
Description: Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
Study NCT01530139 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Level 0
Description: Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
Study NCT03906682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAP Club
Description: RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
Study NCT03906682 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Topics
Description: Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
Study NCT03757923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB PIOGLITAZONE
Description: INSULIN SENSITIZING AGENT
Study NCT03296683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA device imaging
Description: MIRA Device imaging for adjunctive detection of breast cancer
Study NCT04108390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
Study NCT04108390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
Study NCT02322996 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
Study NCT04597450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
Study NCT04597450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period
Study NCT03094728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HLA cross matching
Description: HLA Typing and Mismatch~Cross matching (total and autocross):~Cross match involves placing recipient serum onto donor lymphocytes and a cytotoxic reaction (deemed 'positive') suggests the presence of preformed donor specific antibodies (DSAs),Second, the original crossmatch should be repeated with the addition of the agent Dithiothreitol (DTT). DTT reduces the disulfide bonds in IgM thereby preventing IgM antibodies from generating a positive result.